Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
Aclaris Therapeutics, Inc. (ACRS) entered into an underwriting agreement to issue and sell 7,785,714 common shares and pre-funded warrants to purchase 6,500,000 common shares. The offering price is $3.50 per common share and $3.49999 per pre-funded warrant. Aclaris estimates net proceeds of approximately $46.7 million after underwriting discounts and commissions and estimated offering expenses. Closing is expected on October 28, 2026, subject to customary closing conditions.
The warrants have a $0.00001 per-share exercise price, are exercisable any time after issuance and do not expire until exercised in full. A holder and its affiliates may not exercise if their beneficial ownership would exceed 9.99%; the holder may increase that limit to no more than 19.99%, with any increase effective on the 61st day after notice to Aclaris.
Aclaris Therapeutics, Inc. (ACRS) is offering 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares, plus the common shares issuable upon exercise. The offering prices are $3.50 per common share and $3.49999 per warrant; the exercise price is $0.00001 per share. Aclaris estimates net proceeds of approximately $46.7 million and intends to use them for pipeline research and development, working capital and general corporate purposes.
Phase 1b primary analyses of ATI-052 reported a 45% placebo-adjusted mean EASI improvement at day 57 in atopic dermatitis (58% with ATI-052; 13% with placebo); the per-protocol arms included nine treated patients and one placebo patient. In asthma, day-15 mean FeNO reductions were 59% with ATI-052 and 15% with placebo, with a 200 mL placebo-adjusted and absolute mean FEV1 improvement. Aclaris intends to initiate a Phase 2b ATI-052 trial in eosinophilic esophagitis in early 2027.
Cash, cash equivalents and marketable securities were approximately $204.6 million as of September 30, 2026, an unaudited preliminary estimate. The warrants do not expire and are exercisable at any time after issuance; exercise is subject to an initial 9.99% beneficial-ownership cap, which may be increased to no more than 19.99% on at least 61 days’ prior notice. No established trading market exists for the warrants.
Aclaris Therapeutics, Inc. (ACRS) announced positive primary analysis results from Phase 1b proof-of-concept trials of ATI-052 in atopic dermatitis (AD) and asthma. The company described rapid improvements in skin and itch measures in AD and in fractional exhaled nitric oxide and lung function in asthma. The trials enrolled 14 patients with severe AD and 16 with mild-to-moderate asthma. Across both trials, treatment-emergent adverse events were predominantly Grade 1; there were no Grade 3 or Grade 4 events, adverse-event-related study discontinuations, or observed conjunctivitis.
Aclaris estimated cash, cash equivalents and marketable securities at approximately $204.6 million as of September 30, 2026. The preliminary estimate had not been audited, reviewed or compiled by its independent registered public accounting firm, and actual figures may differ materially. Aclaris intends to prioritize ATI-052 development initially in eosinophilic esophagitis and initiate a Phase 2b trial in early 2027.
Aclaris Therapeutics, Inc. (ACRS) received a Schedule 13G reporting that multiple Frazier Life Sciences-affiliated entities collectively report beneficial ownership positions in its common stock. Frazier Life Sciences Public Fund, L.P. directly holds 7,879,943 shares of common stock, representing 5.4% of the class based on 147,198,893 shares outstanding as of July 31, 2026.
Frazier Life Sciences XI, L.P. holds 86,910 shares (0.1%), and Frazier Life Sciences XII, L.P. holds 762,663 shares (0.5%), with related FHMLSP and FHMLS entities reporting corresponding shared voting and dispositive power. Voting and investment decisions for these funds are made by investment committees, and individual committee members are not attributed beneficial ownership.
RA Capital Management and affiliates reported a significant ownership position in Aclaris Therapeutics, Inc. RA Capital Healthcare Fund, L.P. directly holds 12,723,026 shares of Aclaris common stock. Based on 139,824,273 shares outstanding as of June 30, 2026, this represents 9.1% of the company’s common stock. RA Capital Management, L.P. serves as investment adviser to the Fund and has been delegated sole voting and dispositive power over these shares, while the Fund, RA Capital, Peter Kolchinsky, and Rajeev Shah each disclaim beneficial ownership except for purposes of Section 13(d) reporting.
Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement on August 6, 2026 with Leerink Partners LLC and Cantor Fitzgerald & Co., allowing it to offer and sell shares of common stock from time to time through these firms as sales agents under a Form S-3 shelf.
Sales may be conducted as an “at the market offering” under Rule 415, with Leerink and Cantor using commercially reasonable efforts subject to Aclaris’ instructions. Aclaris will pay a 3.0% commission on gross proceeds, is not obligated to sell any shares, and the prior 2025 agreement allowed sales of up to $100.0 million of common stock.
Aclaris Therapeutics, Inc. has put in place an automatic shelf registration on Form S‑3 as a well‑known seasoned issuer, replacing its prior shelf. The base prospectus covers the potential offering and sale, from time to time, of an indeterminate amount of common stock, preferred stock, debt securities and warrants by the company and any selling securityholders.
The filing also includes a separate prospectus for an “at‑the‑market” equity program allowing Aclaris to issue and sell up to $150,000,000 of common stock through Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents under a sales agreement dated August 6, 2026. Net proceeds, if any, are intended primarily for research and development of its immuno‑inflammatory product candidates, working capital and general corporate purposes, with potential use for complementary acquisitions.
Aclaris is a clinical‑stage biopharmaceutical company focused on novel small and large molecule candidates for immuno‑inflammatory diseases, leveraging its KINect discovery platform. It is classified as a smaller reporting company, which allows reduced disclosure requirements under SEC rules.
Aclaris Therapeutics, Inc. reported Q2 2026 revenue of $1.629 million and a net loss of $21.505 million, bringing first‑half revenue to $3.625 million and net loss to $41.329 million. Performance reflects continued investment in immuno‑inflammatory programs including bosakitug, ATI‑052, modzatinib and ATI‑9494.
Research and development expenses were $18.066 million in Q2 and $33.723 million year‑to‑date, while general and administrative costs reached $6.048 million and $12.791 million. Other income of $2.733 million, mainly interest and non‑cash royalty income, partially offset a Q2 operating loss of $24.238 million.
Cash, cash equivalents and marketable securities totaled $170.6 million at June 30, 2026. Operating activities used $37.996 million of cash in the first half, largely balanced by $57.872 million from equity financing, including a March at‑the‑market sale; a further July ATM raised $40.2 million gross. Management states these resources fund operations for more than 12 months but anticipates ongoing losses and additional future capital needs.
Aclaris Therapeutics, Inc. reported financial results for the quarter and six months ended June 30, 2026 and provided a corporate and clinical update. For the second quarter, total revenue was $1.6 million and net loss was $21.5 million. For the first half of 2026, net loss was $41.3 million, with research and development expenses of $33.7 million driven mainly by ATI-052 and ATI-9494 development, and general and administrative expenses of $12.8 million.
As of June 30, 2026, Aclaris held $170.6 million in cash, cash equivalents and marketable securities and stated that this is expected to fund operations through the end of 2028. After quarter-end, it sold 7.3 million shares via its at-the-market program for $40.2 million in gross proceeds to support planned Phase 2b and proof-of-concept trials. The update highlighted upcoming placebo-controlled top line data from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, a Phase 2 trial of bosakitug in atopic dermatitis, planned Phase 2b programs for ATI-052 and modzatinib, and an expected IND filing for ATI-9494.
Aclaris Therapeutics, Inc. reports that Chief Scientific Officer Roland Kolbeck had 36,375 restricted stock units vest and convert into an equal number of common shares on August 1, 2026. Of these, 12,385 shares were withheld by the company at $5.20 per share to satisfy tax withholding obligations. Following the transactions, Kolbeck retains 109,125 restricted stock units, which vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, conditioned on continued service.